LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Pfizer

Closed

SectorHealthcare

27.06 -1.64

Overview

Share price change

24h

Current

Min

27.02

Max

27.52

Key metrics

By Trading Economics

Income

-5.2B

-1.6B

Sales

903M

18B

P/E

Sector Avg

19.684

57.05

EPS

0.66

Dividend yield

6.38

Profit margin

-9.387

Employees

75,000

EBITDA

-4.9B

756M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+5.44% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

6.38%

2.52%

Next Earnings

5 maj 2026

Next Dividend date

12 cze 2026

Next Ex Dividend date

8 maj 2026

Market Stats

By TradingEconomics

Market Cap

696M

152B

Previous open

28.7

Previous close

27.06

News Sentiment

By Acuity

49%

51%

156 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pfizer Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lut 2026, 12:25 UTC

Earnings

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

20 sty 2026, 10:40 UTC

Acquisitions, Mergers, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 sty 2026, 07:47 UTC

Acquisitions, Mergers, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

11 mar 2026, 11:02 UTC

Market Talk

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

10 mar 2026, 12:50 UTC

Earnings

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10 mar 2026, 11:18 UTC

Earnings

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

9 mar 2026, 09:43 UTC

Hot Stocks

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

10 lut 2026, 21:51 UTC

Earnings

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 lut 2026, 21:17 UTC

Earnings

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3 lut 2026, 21:36 UTC

Earnings

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 lut 2026, 19:56 UTC

Earnings

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 lut 2026, 19:46 UTC

Earnings

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 lut 2026, 17:35 UTC

Earnings

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 lut 2026, 17:30 UTC

Earnings

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

3 lut 2026, 13:50 UTC

Earnings

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 lut 2026, 13:06 UTC

Earnings

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 lut 2026, 12:45 UTC

Earnings

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

3 lut 2026, 12:02 UTC

Earnings

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 lut 2026, 11:48 UTC

Earnings

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

3 lut 2026, 11:48 UTC

Earnings

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

3 lut 2026, 11:47 UTC

Earnings

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

3 lut 2026, 11:46 UTC

Earnings

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

3 lut 2026, 11:45 UTC

Earnings

Pfizer Reaffirms 2026 Guidance >PFE

3 lut 2026, 11:45 UTC

Earnings

Pfizer 4Q Rev $17.56B >PFE

3 lut 2026, 11:45 UTC

Earnings

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

3 lut 2026, 11:45 UTC

Earnings

Pfizer 4Q Adj EPS 66c >PFE

3 lut 2026, 11:45 UTC

Earnings

Pfizer 4Q Loss/Shr 29c >PFE

3 lut 2026, 11:45 UTC

Earnings

Pfizer 4Q Loss $1.65B >PFE

3 lut 2026, 11:45 UTC

Earnings

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

3 lut 2026, 10:41 UTC

Earnings

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

Peer Comparison

Price change

Pfizer Forecast

Price Target

By TipRanks

5.44% upside

12 Months Forecast

Average 29.07 USD  5.44%

High 36 USD

Low 25 USD

Based on 22 Wall Street analysts offering 12 month price targets forPfizer - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

22 ratings

8

Buy

12

Hold

2

Sell

Technical Score

By Trading Central

22.855 / 23.85Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

156 / 349 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat